reference/22715186

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22715186

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Comparative Study\|Journal Article\|Multicenter Study\|Research Support, Non-U.S. Gov't
endingPage	S353
issn	1058-4838 1537-6591
issueIdentifier	s5
pageRange	S341-S353
publicationName	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
startingPage	S341
bibliographicCitation	Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005 Sep 01;41 Suppl 5():S341–53. doi: 10.1086/431675. PMID: 16080072.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c4316b2828b348be17f3dba1cd2adf34 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_258738ba0eb9613a90b40432e34b8ce9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e2c1a4a5bbf8411a945ca6dc167ba7f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d8b434565b6342f8170492f1dceb6322 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b661ef4980365f22342b9aefe68c01dd
date	2005-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1086/431675 https://pubmed.ncbi.nlm.nih.gov/16080072
isPartOf	https://portal.issn.org/resource/ISSN/1537-6591 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1135 https://portal.issn.org/resource/ISSN/1058-4838
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	The Efficacy and Safety of Tigecycline in the Treatment of Skin and Skin‐Structure Infections: Results of 2 Double‐Blind Phase 3 Comparison Studies with Vancomycin‐Aztreonam
discusses	http://id.nlm.nih.gov/mesh/M0305009 http://id.nlm.nih.gov/mesh/M0448397 http://id.nlm.nih.gov/mesh/M0013912 http://id.nlm.nih.gov/mesh/M0022517 http://id.nlm.nih.gov/mesh/M0002090
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D014640Q000627 http://id.nlm.nih.gov/mesh/D000900Q000627 http://id.nlm.nih.gov/mesh/D001398Q000627 http://id.nlm.nih.gov/mesh/D017192Q000188 http://id.nlm.nih.gov/mesh/D008911Q000031
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000078304 http://id.nlm.nih.gov/mesh/D008826 http://id.nlm.nih.gov/mesh/D008911Q000009 http://id.nlm.nih.gov/mesh/D014640Q000009 http://id.nlm.nih.gov/mesh/D001398Q000009 http://id.nlm.nih.gov/mesh/D000900Q000009 http://id.nlm.nih.gov/mesh/D011897 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008911Q000627 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D017192Q000382 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D004359 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D001419Q000187 http://id.nlm.nih.gov/mesh/D000328
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54117 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54686904 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5742832 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5466987 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5459211 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14969 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86741379 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22842006 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56842327 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2274 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247768374 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136104873 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129657207 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129979483

Total number of triples: 70.